- Johnson & Johnson has agreed to buy medical technology firm Guidant for $25.4bn.
- The firm will pay $76 for each Guidant share, 6% more than Wednesday's closing price.
- The deal is aimed at offsetting Johnson & Johnson's reliance on a slowing drug business.
- A number of Johnson & Johnson's products are facing patent expirations, while the company is also battling fierce competition from generic products.
